HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › AXK - Acceler8 Technology Corp.
New Posts  All Forums:Forum Nav:

AXK - Acceler8 Technology Corp.

post #1 of 14
8/8/09 at 9:50pm
Thread Starter 
chart.ashx?t=axk&ta=1&p=d&s=l

Accelr8 Technology Corporation (Accelr8) focuses on developing and commercializing an integrated system to identify bacteria and their mechanisms of antibiotic resistance in critically ill patients. The acquisition of OpTest portfolio of technologies (OpTest) by the Company provided it with a surface chemistry formulation and quantitative bio-analytical measurement instruments. It has supplemented these assets to develop the BACcel technology platform for applications related to rapid identification of bacteria and their antibiotic resistance.
Reply
Reply

Featured Stories on HotStockMarket

thinkorswim Trading platform
e-mini S&P Futures Trading
Educational videos for new investors!
post #2 of 14
8/8/09 at 9:51pm
Thread Starter 
trend reversal going on...although on light...real light volume...

Reply
Reply
post #3 of 14
10/17/09 at 6:37pm
might be worth keeping a watch on this one now.
Reply
Reply
post #4 of 14
10/17/09 at 6:40pm
Thread Starter 
yepper...after falling off that cliff...wow...thats a great example of why i wait longer than many on my entry points...may miss some of a run once in a while but it does save me lots o money many times too...putting it on radar again now...
Reply
Reply
post #5 of 14
10/18/09 at 1:56am
They lost their MAJOR development firm on the 25th. AKA the company helping them develop stuff decided to take the knowledge and run so they can complete it on their own to make more money.

Accelr8 and Becton Dickinson Conclude Technical Development Project
bwi | Sep 25, 10:14 AM
Content Name: AdsForNewsDetailCenterColumn

Accelr8 and Becton Dickinson Conclude Technical Development Project
Sep. 25, 2009 (Business Wire) -- Accelr8 Technology Corporation (NYSE Amex: AXK) announced today that it has concluded a technical development project with Becton, Dickinson and Company (“BD”) (NYSE: BDX). Accelr8’s technology met formal testing requirements for identification of a subset of relevant species of bacteria. However, BD advised the Company that it has decided to decline an associated exclusive technology license option. At any time, BD has numerous new product opportunities, and prioritizes projects on the basis of decision criteria that are not limited to technical factors.

According to David Howson, Accelr8’s president, “We’re disappointed by BD’s decision not to exercise its exclusive option. Nevertheless, we made substantial advances and gained strong supporting technical evidence in the project, including integrated testing using patient specimens. We will continue discussions with other prospective collaborators. The BACcel™ rapid diagnostic system remains the only technology yet supported by published data to have the capability to provide same-day analysis of all significant highly drug-resistant bacteria and their particular resistance mechanisms.”

I dont know if I would watch this one.... looks like most of the holders got off the boat its at a 5yr low ot top of the .05/share loss last quarter.
Reply
Reply
post #6 of 14
10/21/09 at 4:09pm
nice little gain today so far.
Reply
Reply
post #7 of 14
11/1/09 at 7:34pm
Thread Starter 
Quote:
Originally Posted by kevin1612 View Post
trend reversal going on...although on light...real light volume...


did hang in there last week...but that volume...looking for the 1.10s to hold up then pump up the vol a bit...or a lot...
Reply
Reply
post #8 of 14
3/4/10 at 2:40am
just came across this, looks like break of .80 on some volume could lead to 1.00

chart.ashx?t=axk&ta=1&p=d&s=l
stock-chart-str.aspx?id=axk&ca=24062939
Reply
Reply
post #9 of 14
5/19/11 at 3:27pm
Wedge / Fry pan breakout, looks nice here. Just be forewarned it is a very thin trader so either you like that or want to keep your position very small.
Reply
Reply
post #10 of 14
5/31/11 at 10:39am

Looking good today for some reason, no new news.

Reply
Reply
post #11 of 14
4/25/12 at 3:14pm
Thread Starter 
Accelr8 Technology: Group To Invest Up To $35M
1 days 23 hours 27 minutes ago - Dow Jones News


DOW JONES NEWSWIRES

Accelr8 Technology Corp. (AXK) said an investment group that includes two founders of private-investment firm Crabtree Partners LLC agreed to make a potential stock investment of $35 million, as the company raises funds to bring its diagnostic testing system for bacterial and fungal pathogens to market.
Shares more than doubled to $2.33 in recent trading.
The investor group includes Jack Schuler, John Patience and Larry Mehren.
Mehren will become Accelr8's chief executive when the deal closes. Most recently he served as the head of global business and chief operating officer of Roche Tissue Diagnostics.
Under the deal, expected to close by July 1, the investor group will purchase 14 million Accelr8 shares at $1.03 each, representing a slight discount from Friday's close at $1.04. The group also will be issued 7 million warrants with an exercise price of $1.03 and another 7 million warrants with an exercise price of $2.
Accelr8 had about 11 million shares outstanding as of Jan. 31.
Schuler and Patience are principals and founders of Crabtree. Before founding Crabtree, Schuler was president and chief operating officer of Abbott Laboratories (ABT). Schuler also is a principal shareholder and director of diagnostics firm Quidel Corp. (QDEL). Patience headed the worldwide healthcare consulting practice of McKinsey & Co., Inc. and was a co-founder of Marquette Venture Partners.
Reply
Reply
post #12 of 14
4/25/12 at 3:15pm
Thread Starter 
Crabtree Partners and Larry Mehren to invest $35 million in Accelr8 Technology
1 days 31 minutes ago - Datamonitor Financial Deals Tracker via Comtex
Crabtree Partners LLC and Larry Mehren have agreed to make an investment of approximately $35 million in Accelr8 Technology Corporation, a US-based developer of materials and instrumentation for applications in medical diagnostics, basic research, drug discovery, and bio-detection. Both the entities are based in the US.

Crabtree Partners in a private investment firm founded by Jack Schuler and John Patience.

Under the terms of the transaction, the investors will purchase 14 million shares of Accelr8's common stock at a price of $1.03 per share for an initial investment of $14.42 million. The investors will also be issued a total of 7 million warrants exercisable at $1.03, and 7 million warrants exercisable at $2.

The transaction is expected to close by July 1, 2012.

Deal Value (US$ Million) 35
Deal Type Private Equity
Sub-Category DIRECT INVESTMENT
Deal Status Announced: 2012-04-23
Deal Participants

Target (Company) Accelr8 Technology Corporation
Deal Rationale

Accelr8 will use the proceeds to complete the product development and market introduction of its BACcel(TM) culture-free, diagnostic system for same-shift identification and antibiotic resistance testing of bacterial and fungal pathogens.
Reply
Reply
post #13 of 14
4/25/12 at 3:16pm
Thread Starter 
not giving back much of the 150% one day gains earlier this week


425
Reply
Reply
post #14 of 14
4/27/12 at 2:50pm
Thread Starter 
holding up quite well aft big pop to resist

425
Reply
Reply
New Posts  All Forums:Forum Nav:
  Return Home
  Back to Forum: Penny Stocks

Featured Stories on HotStockMarket

thinkorswim Trading platform
e-mini S&P Futures Trading
Educational videos for new investors!
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › AXK - Acceler8 Technology Corp.